Mingot-Castellano, María EAlcalde-Mellado, PatriciaPascual-Izquierdo, CristinaPerez Rus, GloriaCalo Pérez, AidaMartinez, María PLópez-Jaime, Francisco JAbalo Perez, LorenaGonzalez-Porras, José RLópez Fernández, FernandaCaparrós Miranda, Isabel SGonzález-López, Tomás JMoreno Beltrán, María ERubio Escuin, RebecaJimenez Bárcenas, Reyeson behalf GEPTI (Grupo Español de Trombocitopenia Inmune)2023-02-092023-02-092021-05-15http://hdl.handle.net/10668/17793Infections are one of the well-known precipitating factors for relapses in patients with immune thrombocytopenia (ITP). Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection can sometimes lead to or be associated with thrombocytopenia due to an increase in peripheral platelet destruction from inflammatory hyperactivation. Currently, we do not know if SARS-CoV-2 infection modifies the natural evolution of chronic or persistent ITP or if previous immunosuppression of patients with ITP influences the incidence and severity of coronavirus disease 2019 (COVID-19) in this group. The present study was an observational, multicentre, national series of 32 adult patients with pre-existing ITP and subsequent SARS-CoV-2 infection, collected by the Spanish ITP Group [Grupo Español de Trombocitopenia Inmune (GEPTI)].enCOVID-19ITPchronicpersistentsteroidstreatmentAdultAgedAged, 80 and overCOVID-19FemaleHumansIncidenceMaleMiddle AgedPurpura, Thrombocytopenic, IdiopathicSARS-CoV-2Spainresearch article33991422open access10.1111/bjh.175061365-2141PMC8239889https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239889https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239889/pdf